Gensight Biologics SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0013183985
EUR
0.09
0 (-2.84%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 20 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.43

stock-summary
Return on Equity

61.76%

stock-summary
Price to Book

-0.62

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-14.5%
0%
-14.5%
6 Months
-43.0%
0%
-43.0%
1 Year
-62.17%
0%
-62.17%
2 Years
-78.41%
0%
-78.41%
3 Years
-96.06%
0%
-96.06%
4 Years
-97.37%
0%
-97.37%
5 Years
-98.81%
0%
-98.81%

Gensight Biologics SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
3.54%
EBIT Growth (5y)
10.33%
EBIT to Interest (avg)
-18.86
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.42
Sales to Capital Employed (avg)
0.03
Tax Ratio
7.31%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.62
EV to EBIT
-2.11
EV to EBITDA
-2.19
EV to Capital Employed
-1.82
EV to Sales
33.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Gensight Biologics SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 15.38% vs -50.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 46.56% vs 5.07% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.50",
          "val2": "1.30",
          "chgp": "15.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.80",
          "val2": "-28.40",
          "chgp": "44.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.50",
          "val2": "3.20",
          "chgp": "-21.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "4.10",
          "val2": "6.80",
          "chgp": "-39.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.00",
          "val2": "-26.20",
          "chgp": "46.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-11,292.70%",
          "val2": "-24,776.60%",
          "chgp": "1,348.39%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
1.50
1.30
15.38%
Operating Profit (PBDIT) excl Other Income
-15.80
-28.40
44.37%
Interest
2.50
3.20
-21.88%
Exceptional Items
4.10
6.80
-39.71%
Consolidate Net Profit
-14.00
-26.20
46.56%
Operating Profit Margin (Excl OI)
-11,292.70%
-24,776.60%
1,348.39%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 15.38% vs -50.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 46.56% vs 5.07% in Dec 2023

stock-summaryCompany CV
About Gensight Biologics SA stock-summary
stock-summary
Gensight Biologics SA
Pharmaceuticals & Biotechnology
Gensight Biologics SA is a France-based biopharmaceutical company. The Company develops and commercializes gene therapy-based treatments of retinal degenerative diseases. It develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The Company intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
Company Coordinates stock-summary
Company Details
74 rue du Faubourg Saint Antoine , PARIS None : 75012
Registrar Details